Triazole oxadiazoles derivatives
By developing selective S1P1/Edg1 receptor agonists, we have solved the problems of insufficient immunosuppressive activity and poor high-dose tolerance of existing S1P1 agonists in the treatment of multiple sclerosis, achieving higher efficacy and safety, combined with Immunomodulators to enhance therapeutic effects.
Patent Information
- Application Number
- CN200880125323.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2008-02-20
- Filing Date
- 2008-12-17
- Publication Date
- 2010-12-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing S1P1 agonists have problems with insufficient immunosuppressive activity and poor high-dose tolerance when treating multiple sclerosis. They also lack selectivity, affecting efficacy and safety.
Developed a selective S1P1/Edg1 receptor agonist that exhibits excellent selectivity compared to the S1P3/Edg3 receptor, combined with an immunomodulator to improve the therapeutic window of lymphocyte sequestering agents and enhance high-dose tolerance of the drug sex.
As a selective S1P1 agonist, the compound significantly improves the efficacy of treating multiple sclerosis, expands the therapeutic window, enhances drug tolerance, and can be used in combination with other active compounds to improve vascular function and immune regulation.